Evolus (NASDAQ:EOLS) and Chugai Pharmaceutical (OTCMKTS:CHGCY) Critical Contrast

Chugai Pharmaceutical (OTCMKTS:CHGCY) and Evolus (NASDAQ:EOLS) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Volatility and Risk

Chugai Pharmaceutical has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Valuation and Earnings

This table compares Chugai Pharmaceutical and Evolus”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chugai Pharmaceutical	$8.41 billion	8.45	$2.91 billion	$0.92	23.47
Evolus	$316.49 million	1.94	-$51.64 million	($0.52)	-17.88

Chugai Pharmaceutical has higher revenue and earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Chugai Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Chugai Pharmaceutical and Evolus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chugai Pharmaceutical	35.09%	23.76%	19.92%
Evolus	-10.85%	N/A	-13.00%

Insider & Institutional Ownership

0.0% of Chugai Pharmaceutical shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 5.0% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Chugai Pharmaceutical and Evolus, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chugai Pharmaceutical	0	3	1	1	2.60
Evolus	1	1	4	0	2.50

Evolus has a consensus target price of $14.50, suggesting a potential upside of 55.91%. Given Evolus’ higher possible upside, analysts clearly believe Evolus is more favorable than Chugai Pharmaceutical.

Summary

Chugai Pharmaceutical beats Evolus on 10 of the 15 factors compared between the two stocks.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

About Evolus

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.